MedTrace Logo

Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes

NCT02641522 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2018-11-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the effects of siltuximab on immune cell functions in patients with Type 1 diabetes (T1D).

Conditions

Interventions

DRUG

Siltuximab

Single infusion of siltuximab (11 mg/kg)

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    collaborator INDUSTRY

  • Carla Greenbaum, MD

    lead OTHER

Principal Investigators

  • Carla Greenbaum, MD · Benaroya Research Institute

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-08
Primary Completion
2017-03-16
Completion
2017-03-16

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02641522 on ClinicalTrials.gov